Cytokinetics director receives 272-share stock award

HENDERSON JOHN T reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

HENDERSON JOHN T reported acquisition or exercise transactions in this Form 4 filing.

Cytokinetics Inc director John T. Henderson received a grant of 272 shares of common stock on 2026-07-15 at 82.62 per share under the company’s Equity in lieu of Cash Retainer Program. The shares are fully vested, bringing his direct holdings to 78,360 shares and indirect spouse-held holdings to 83 shares.

Insider Trade Summary

Grant/Award: 272 shares

Grant/Award 2 txns

Insider HENDERSON JOHN T

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	272	$82.62	$22K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 78,360 shares (Direct); Common Stock — 83 shares (Indirect, by Spouse)

Footnotes (1)

1. F1. Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

Key Figures

Shares granted: 272 shares Grant price per share: 82.62 per share Direct holdings after transaction: 78,360 shares +1 more

4 metrics

Shares granted 272 shares Grant of common stock on 2026-07-15 under Equity in lieu of Cash Retainer Program

Grant price per share 82.62 per share Price per share for the 272-share stock grant on 2026-07-15

Direct holdings after transaction 78,360 shares Total direct Cytokinetics common stock held by Henderson after the grant

Indirect spouse-held shares 83 shares Common stock reported as indirectly owned, described as by Spouse

Key Terms

Equity in lieu of Cash Retainer Program, fully vested, indirect ownership

3 terms

Equity in lieu of Cash Retainer Program financial

"granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program"

fully vested financial

"Shares are fully vested at the time of grant"

indirect ownership financial

"Ownership type listed as indirect with nature of ownership described as by Spouse"

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/16/2026 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENDERSON JOHN T

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A(1)		272	A	$82.62	78,360	D
Common Stock								83	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

	/s/ John O. Faurescu, attorney-in-fact for Dr. Henderson	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)